Compare · NVO vs PPCB
NVO vs PPCB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Propanc Biopharma Inc. (PPCB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PPCB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 62145.3x PPCB ($3.1M).
- Over the past year, NVO is down 45.0% and PPCB is down 95.6% - NVO leads by 50.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for PPCB).
- NVO has more recent analyst coverage (25 ratings vs 0 for PPCB).
- Company
- Novo Nordisk A/S
- Propanc Biopharma Inc.
- Price
- $43.29+1.17%
- $3.29+132.51%
- Market cap
- $191.15B
- $3.1M
- 1M return
- -7.90%
- +46.03%
- 1Y return
- -45.02%
- -95.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PPCB
- ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity.
- Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
- Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain
- Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
- Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
- Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
- SEC Form 10-Q filed by Propanc Biopharma Inc.
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
- SEC Form EFFECT filed by Propanc Biopharma Inc.
- SEC Form S-1 filed by Propanc Biopharma Inc.